Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:ENP)
ASX:ENP
ENP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Tryptamine Therapeutics News
ENP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.05 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$49.89M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Undervalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,609,510,100 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ENP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tryptamine Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.21%
12-Months-Change
Fundamentals
Return on Equity
-94.13%
Trailing 12-Months
Asset Growth
-8.94%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.